Project Grant R01HD113290

Award Date 7/1/24
Completion Date 4/30/28
Dollars Obligated $2M
Federal Grant Program
93.865
Assistance Type
Project Grant
Place of Performance
Fort Collins, CO 80521, USA
Similar Awards
This Project Grant award from the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to develop a modern Electrical Impedance Tomography (EIT) device for monitoring children in the Intensive Care Unit (ICU). The $299,900 award to Goodlife Inventors LLC will fund efforts to (1) generate initial designs for an advanced lightweight EIT belt and (2) assess the technical feasibility of a miniaturized, easier to use EIT core device. If...
The National Institute of Child Health and Human Development (NICHD) awarded a $250,300 Project Grant (CFDA 93.865 - Child Health and Human Development Extramural Research) to Children's Mercy Hospital to conduct a Phase I clinical study investigating the use of inhaled ciclesonide, a synthetic glucocorticoid, for preventing bronchopulmonary dysplasia (BPD) in preterm infants born before 30 weeks gestation. The study aims to determine the maximum tolerable dose of inhaled ciclesonide that does...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $773,916 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Children's Hospital Medical Center in Cincinnati, Ohio. The 5-year grant, which runs from August 2024 to June 2029, aims to create and validate a tool to calculate the contribution of each phenotype of bronchopulmonary dysplasia (BPD) to elevated breathing effort, known as the work of breathing (WOB), in premature neonates. The research...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $295,924 to Convergent Engineering, Inc. to develop a prototype decision support system for personalized mechanical ventilation care. The system aims to simplify the use of esophageal pressure measurements to optimize ventilator settings and prevent complications for ventilated patients. The project has two key objectives: 1) Building a...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $2,070,206 to Ann & Robert H Lurie Children's Hospital of Chicago to conduct research on endotypes of bronchopulmonary dysplasia (BPD) in premature infants. The research aims to leverage existing genetic and longitudinal clinical data from approximately 2,000 former premature children to characterize the long-term...
This $600,761 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to understand the role of the NKG2D receptor and its ligands in driving lung inflammation and development of bronchopulmonary dysplasia (BPD) in preterm infants. The key objectives are to: 1) Investigate the contribution of NKG2D+ lung lymphocytes (gamma-delta T cells and NK cells) to LPS- and hyperoxia-induced lung...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), totaling $645,450.00 supports research to investigate the mechanisms by which exposure to hyperoxia (supplemental oxygen) in preterm infants leads to decreased angiogenesis (blood vessel growth) and the development of bronchopulmonary dysplasia (BPD), a common complication of premature birth. The research, conducted at the Medical...
This is a Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research (CFDA 93.837) program. The $827,682 award will fund a comprehensive research project to develop advanced imaging techniques, including dynamic contrast-enhanced CT, dual-energy CT, and electrical impedance tomography, to characterize pulmonary perfusion and guide personalized treatment of acute respiratory distress...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support the development of a hand-held smart sensor system to detect exhaled volatile organic compound (VOC) biomarkers for the noninvasive, real-time identification of pulmonary exacerbations in children with cystic fibrosis. The $206,345 grant, awarded to the Trustees of Indiana University, doing business as Indiana University...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $873,736 project grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Children's Hospital Los Angeles (CHLA) to study risk stratification markers for pediatric acute respiratory distress syndrome (ARDS). The project aims to validate the use of the end tidal alveolar dead space fraction (AVDSF) as a superior marker for mortality risk compared to oxygenation index (OI), as well as determine if AVDSF can identify...

REAL-TIME EIT PULMONARY IMAGING FOR INFANTS REQUIRING VENTILATORY THERAPY - PROJECT SUMMARY BRONCHOPULMONARY DYSPLASIA (BPD) IS THE MOST COMMON MORBIDITY OF PREMATURITY WITH OVER 10,000 INFANTS DIAGNOSED EACH YEAR IN THE UNITED STATES. UNDERDEVELOPED LUNGS AT BIRTH, THE NEED FOR VENTILATORY SUPPORT, WHICH MAY RESULT IN VENTILATOR-INDUCED LUNG INJURY, AND OTHER FACTORS RESULT IN SIGNIFICANT STRUCTURAL AND FUNCTIONAL PULMONARY ABNORMALITIES ASSOCIATED WITH SHORT- AND LONG-TERM LUNG DISEASE. EFFECTIVE MANAGEMENT INCLUDES AN INDIVIDUALIZED APPROACH TO CHOOSING THE RIGHT VENTILATION STRATEGY AND MEDICATIONS. TWO IMPORTANT TECHNIQUES INCLUDE THE USE OF A LONG I-TIME VENTILATORY STRATEGY AND ADMINISTRATION OF BRONCHODILATORS. HOWEVER, EACH OF THESE TREATMENTS HAS SOME ASSOCIATED RISK, AND THERE IS CURRENTLY NO REAL-TIME METHOD TO ASSESS THEIR EFFECTIVENESS ON IMPROVING VENTILATION AND PERFUSION. ELECTRICAL IMPEDANCE TOMOGRAPHY (EIT) IS A NONINVASIVE, NON-IONIZING REAL-TIME FUNCTIONAL IMAGING TECHNIQUE WITH NO HARMFUL SIDE EFFECTS, SUITABLE FOR PATIENTS OF ANY AGE. WE HYPOTHESIZE THAT EIT IMAGES AND DERIVED MEASURES CAN PROVIDE REAL-TIME, ACTIONABLE INFORMATION TO GUIDE THE CLINICIAN'S TREATMENT STRATEGY IN INFANTS WITH BPD, AND SATISFY THIS UNMET NEED. IN THIS PROPOSAL WE WILL CARRY OUT THE FOLLOWING SPECIFIC AIMS: (1) BUILD A NEW ADAPTIVE CURRENT TOMOGRAPHY SYSTEM DESIGNED FOR 3D IMAGING OF VERY YOUNG INTUBATED INFANTS INCLUDING NOVEL 3-D RECONSTRUCTION ALGORITHMS TO PROVIDE REAL-TIME IMAGES OF REGIONAL VENTILATION, PULSATILE PERFUSION AND QUANTITATIVE EIT-DERIVED MEASURES. (2) ASSESS THE ABILITY OF EIT IMAGES AND DERIVED MEASURES TO DETERMINE THE EFFECTIVENESS OF LONG I-TIME VENTILATION STRATEGIES WHILE THEY ARE BEING APPLIED. AN EIT VISUALIZATION PLATFORM WILL BE DEVELOPED TO ENABLE THE CLINICIAN TO VISUALIZE THE IMAGES AND OUTPUT MEASURES TO ASSESS TREATMENT EFFECTIVENESS. (3) DETERMINE WHAT COMBINATION OF EIT- DERIVED MEASURES PROVIDES THE BEST ASSESSMENT OF BRONCHODILATOR RESPONSIVENESS (BDR) IN INFANTS WITH OR AT RISK OF BPD AFTER THE FIRST ADMINISTRATION OF BRONCHODILATOR THERAPY. WE WILL EVALUATE THE EFFICACY IN AIMS 2 AND 3 IN A STUDY WITH INFANTS ENROLLED FROM THE LEVEL IV NICU AT STANFORD UNIVERSITY MEDICAL CENTER AND THE UNIVERSITY OF COLORADO HOSPITAL NEONATAL INTENSIVE CARE UNIT.

Posted 6/28/24, 12:00 AM